Skip to main content

Advertisement

SpringerLink
Log in

Efficacy of fluconazole in the treatment of systemic fungal infections

  • Article
  • Published:
European Journal of Clinical Microbiology and Infectious Diseases Aims and scope Submit manuscript

Abstract

The efficacy of fluconazole in the treatment of systemic fungal infections was evaluated in an open non-comparative trial. A total of 48 patients with proven or suspected fungal infections were enrolled in 40 of whom efficacy was evaluable.Candida albicans accounted for 90 % of the infections.Candida parapsilosis, Candida glabrata, Histoplasma capsulatum andAspergillus fumigatus caused the infection in one case each. Fluconazole was administered at a dosage of 200–400 mg daily for a mean duration of 15 days. Fluconazole treatment was successful in 53 % of the patients. In patients with proven or probableCandida albicans infections a clinical and mycological response was achieved in 62 % and 65 %, respectively. In 11 patients elevation of liver enzymes was considered to be possibly related to fluconazole treatment; modification of treatment was not necessary in any case. Fluconazole was found to be a well tolerated and effective agent for the treatment of systemicCandida albicans infections.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  1. Horn R, Wong B, Kiehn T, Armstrong D: Fungemia in a cancer hospital: changing frequency, earlier onset, and results of therapy. Reviews of Infectious Diseases 1985, 7: 646–655.

    PubMed  Google Scholar 

  2. Meunier F: Fungal infections in the compromised host. In: Rubin RH, Young LS (ed): Clinical approach to infection in the compromised host. Plenum Medical, New York, 1988, p. 193–220.

    Google Scholar 

  3. Walsh TJ, Pizzo A: Treatment of systemic fungal infections: recent progress and current problems. European Journal of Clinical Microbiology and Infectious Diseases 1988, 7: 460–475.

    Google Scholar 

  4. Van den Bossche H: Biochemical targets for antifungal azole derivatives: hypothesis on the mode of action. In: McGinnis M (ed): Current topics in medical mycology. Springer Verlag, New York, 1985, p. 313–351.

    Google Scholar 

  5. Odds FC, Cheesman SL, Abbott AB: Antifungal effects of fluconazole (UK-49858), a new triazole antifungal, in vitro. Journal of Antimicrobial Chemotherapy 1986, 18: 473–478.

    PubMed  Google Scholar 

  6. Hughes CE, Beggs WH: Action of fluconazole (UK-49,858) in relation to other systemic antifungal azoles. Antimicrobial Agents and Chemotherapy 1987, 19: 171–174.

    Google Scholar 

  7. Rogers TE, Galgiani JN: Activity of fluconazole (UK-49,858) and ketoconazole againstCandida albicans in vitro and in vivo. Antimicrobial Agents and Chemotherapy 1986, 30: 418–422.

    PubMed  Google Scholar 

  8. Graybill JR: Fluconazole efficacy in animal models of systemic mycosis. In: Fromtling RA (ed): Recent trends in the discovery, development and evaluation of antifungal agents. R.J. Prous Science, Barcelona, 1987, p. 113–124.

    Google Scholar 

  9. Arndt CA, Walsh TJ, McCully CL, Balis FM, Pizzo PA, Poplac DG: Fluconazole penetration into cerobrospinal fluid: Implications for treating fungal infections of the central nervous system. Journal of Infectious Diseases 1988, 157: 178–180.

    PubMed  Google Scholar 

  10. Humphrey MJ, Jevons S, Tarbit MH: Pharmacokinetic evaluation of UK-49,858, a metabolically stable triazole antifungal drug, in animals and humans. Antimicrobial Agents and Chemotherapy 1985, 28: 648–653.

    PubMed  Google Scholar 

  11. Meunier F, Gerain J, Snoeck R, Libotte F, Lambert C, Ceupens AM: Fluconazole therapy of oropharyngeal candidiasis in cancer patients. In: Fromtling RA (ed): Recent trends in the discovery, development and evaluation of antifungal agents. R.J. Prous Science, Barcelona, 1987, p. 169–174.

    Google Scholar 

  12. Dupont B, Drouhet E: Fluconazole in the management of oropharyngeal candidiasis in a predominantly HIV antibody-positive group of patients. Journal of Medical and Veterinary Mycology 1988, 26: 67–71.

    PubMed  Google Scholar 

  13. Meunier F, Aoun M, Gerard M: Therapy of oropharyngeal candidiasis in the immunocompromised host: A randomised double-blind study of fluconazole vs. ketoconazole. Reviews of Infectious Diseases 1990, 12: 364–368.

    PubMed  Google Scholar 

  14. Brammer KW (Multicenter Study Group): Treatment of vaginal candidiasis with a single dose of fluconazole. European Journal of Clinical Microbiology and Infectious Diseases 1988, 7: 364–367.

    Google Scholar 

  15. Dupont B, Drouhet E: Cryptococcal meningitis and fluconazole. Annals of Internal Medicine 1987, 106: 778–784.

    Google Scholar 

  16. Saag MS, Powderly WG, Cloud GA, Robinson P, Grieco MH, Sharkey PK, et al.: Comparison of amphotericin B with fluconazole in the treatment of acute AIDS-associated cryptococcal meningitis. New England Journal of Medicine 1992, 326: 83–89.

    PubMed  Google Scholar 

  17. Müller F, Hund M, Löhr J, Lode H, Wagner J, Fangmann W: Sepsis 1979 bis 1986. Epidemiologie, Atiologie, Klinik und Prognose bei 691 Patienten. Medizinische Klinik 1989, 84: 323–328.

    PubMed  Google Scholar 

  18. Powderly WG, Saag MS, Cloud GA, Robinson P, Meyer RD, Jacobson JM, et al.: A controlled trial of fluconazole or amphotericin B to prevent relapse of cryptococcal meningitis in patients with the acquired immunodeficiency syndrome. New England Journal of Medicine 1992, 326: 793–798.

    PubMed  Google Scholar 

  19. Goodman JL, Winston DJ, Greenfield RA, Chandrasekar PH, Fox B, Kaizer H, et al.: A controlled trial of fluconazole to prevent fungal infections in patients undergoing bone marrow transplantation. New England Journal of Medicine 1992, 326: 845–851.

    PubMed  Google Scholar 

  20. Van't Wout JW, Mattie H, van Furth R: A prospective study of the efficacy of fluconazole (UK-49,858) against deep-seated fungal infections. Journal of Antimicrobial Chemotherapy 1988, 21: 665–672.

    PubMed  Google Scholar 

  21. Kujath P, Lerch K: Secondary mycosis in surgery: treatment with fluconazole. Infection 1989, 17: 111–117.

    Article  PubMed  Google Scholar 

  22. Fainstein V, Bodey GP, Elting L, Maksymiak A, Keating M, McCredie KB: Amphotericin B or ketoconazole therapy of fungal infections in neutropenic cancer patients. Antimicrobial Agents and Chemotherapy 1987, 31: 11–15.

    PubMed  Google Scholar 

  23. Wey SB, Mori M, Pfaller MA, Woolson RF, Wenzel RP: Hospital acquired candidemia: the attributable mortality and excess length if stay. Archives of Internal Medicine 1988, 148: 2642–2645.

    Article  PubMed  Google Scholar 

  24. Warnock DW, Burke J, Cope NJ, Johnson EM, Von Frauenhofer NA, Williams EW: Fluconazole resistance inCandida glabrata. Lancet 1988, ii: 1310.

    Article  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Clinical Microbiology, Technical University of Munich, Trogerstr, 32, 8000, Munich 80, Germany

    D. Milatovic & A. Voss

Authors
  1. D. Milatovic
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. A. Voss
    View author publications

    You can also search for this author in PubMed Google Scholar

Rights and permissions

Reprints and permissions

About this article

Cite this article

Milatovic, D., Voss, A. Efficacy of fluconazole in the treatment of systemic fungal infections. Eur. J. Clin. Microbiol. Infect. Dis. 11, 395–402 (1992). https://doi.org/10.1007/BF01961853

Download citation

  • Issue Date:

  • DOI: https://doi.org/10.1007/BF01961853

Keywords

Search

Navigation